Stefan Posse1,
2, Tongsheng Zhang1, Melanie E. Royce, 23,
Zoneddy Ruiz Dayao, 23, Susan Lopez2, Laurel Sillerud4,
Claudia Wuillma Narvaez Villarrubia5, Steven Eberhardt, 26,
Lesley Carol Lomo, 27, Ashwani Rajput, 28, John
Russell, 28, Linda Casey9, Patrick J. Bolan10,
11
1Neurology,
University of New Mexico, Albuquerque, NM, United States; 2UNM
Cancer Center, University of New Mexico, Albuquerque, NM, United States; 3Medical
Oncology, University of New Mexico, Albuquerque, NM, United States; 4Biochemistry,
University of New Mexico, Albuquerque, NM, United States; 5Center
for Emerging Energy Technology, University of New Mexico, Albuquerque, NM,
United States; 6Radiology, University of New Mexico, Albuquerque,
NM, United States; 7Pathology, University of New Mexico,
Albuquerque, NM, United States; 8Surgery, University of New
Mexico, Albuquerque, NM, United States; 9Radiology, Nex Mexico
Cancer Center, Albuquerque, NM, United States; 10Center for
Magnetic Resonance Research, University of Minnesota, Minnesota, MN, United
States; 11Radiology, University of Minnesota, Minnesota, MN,
United States
Thirteen patients with biopsy-confirmed, infiltrating ductal carcinoma were studied at 3 Tesla to monitor changes in total Choline during neoadjuvant therapy in comparison with dynamic contrast enhanced (DCE) MRI, and to investigate association of total Choline with receptor status. 3D lipid suppressed Proton-Echo-Planar-Spectroscopic-Imaging (PEPSI) was performed with 1 cc voxel size using a 10 min scan protocol that included a water reference scan. Decreases in concentration and/or volume of total Choline preceded the decreases in tumor volume measured with DCE-MRI in 4 of the 6 patients followed during neoadjuvant therapy. The concentration and spatial extent of total Choline was more strongly elevated in triple negative tumors compared to non-triple negative tumors and not detectable in triple positive tumors.